Phase II Study of Resistant Potato Starch Plus Deferasirox to Improve Outcomes in Patients Undergoing Allogeneic Stem Cell Transplantation

Inclusion Criteria: * Patients with hematologic disorders undergoing allo-HCT from fully HLA-matched unrelated or related donors after full-intensity conditioning regimen * Age ≥18 years * Karnofsky performance status \>70%, see Appendix A * Patients must be able to swallow capsules/tablets * Ability to understand and the willingness to sign a written informed consent * Availability of a full-HLA matched related or unrelated donor who is medically eligible to donate cells according to the National Marrow Donor Program criteria Exclusion Criteria: * Patients with active inflammatory bowel disease requiring treatment per treating investigator * Patients with a history of gastric bypass surgery * Patients with active Clostridium difficile infection at the time of study enrollment. Active infection is defined as a stool sample positive for Clostridium difficile toxin via enzyme immunoassay (EIA) and either symptoms (frequent loose stools) OR imaging findings consistent with toxic megacolon * Patients with active iron deficiency anemia requiring treatment * Patients with iron overload receiving active treatment with deferasirox * Known hypersensitivity to deferasirox or any component of Jadenu or Exjade * Patients actively enrolled on treatment or in follow up phase on any other GVHD prevention trial * Any physical or psychological condition that, in the opinion of the investigator, would pose an unacceptable risk to the patient or raise concern that the patient would not compl…